02877 SHINEWAY PHARM
- 8.630
- -0.110-1.26%
SHINEWAY PHARM News
Changes in the Chinese herbal medicine cycle? As gross profit declines, pharmaceutical companies face price increase options|New cycle of traditional Chinese medicine
“After three years of increase, three years of decline, and three years of flat rate, the cycle of changes in the price of Chinese herbal medicines is generally ten years.” Based on the characteristics of this cycle, at the end of 2023, some people in the Chinese herbal medicine industry expect “the price of Chinese herbal medicines has been rising for three years and should fall back.” However, in the first half of this year, the price of Chinese herbal medicines continued to rise after a brief adjustment at a high level.
The Chinese Medicine Industry in the Next Twenty Years: Pharmaceutical Companies Lay Out Yinfa Economy and OTC Market|A New Cycle of Traditional Chinese Medicine
Currently, there are two obvious trends in the traditional Chinese medicine industry — the number of companies participating in the OTC market conference has increased markedly; capital and companies' attention to geriatric market products has increased markedly.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Express News | Shenwei Pharmaceutical: Revenue in the management accounts in the first quarter was 1,118 billion yuan without auditor review, a decrease of 6.1% over the previous year
神威藥業：年度報告 2023
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
SHINEWAY PHARM To Go Ex-Dividend On April 29th, 2024 With 0.461 HKD Dividend Per Share
March 30th - $SHINEWAY PHARM(02877.HK)$ is trading ex-dividend on April 29th, 2024. Shareholders of record on April 30th, 2024 will receive 0.461 HKD dividend per share on May 17th, 2024. The ex-d
China Shineway Pharmaceutical Group Grows 2023 Profit, Declares Interim 2024 Dividend
China Shineway Pharmaceutical Group (HKG:2877) posted a 2023 profit of 969.5 million yuan, or 1.28 yuan per share, up from 722.8 million yuan, or 0.96 yuan per share, a year earlier. The pharmaceutica
Shenwei Pharmaceutical (02877.HK)'s profit of RMB 969.5 million increased 34.1% year-on-year in 2023
Gelonghui, March 28, 丨 Shenwei Pharmaceutical (02877.HK) announced that for the year ended December 31, 2023, turnover was RMB 4,516 million, up 14.3% from last year; annual profit was RMB 969.5 million, up 34.1% from last year; earnings per share was RMB 128 points; declared the first interim dividend in 2024 of RMB 43 points per share; net assets of RMB 8.51 per share (equivalent to HK$9.36); and net cash per share of RMB 6.76 (equivalent to HK$7.43). In 2023, with the normalization of centralized procurement and
Shenwei Pharmaceutical (02877) will pay an interim dividend of HK$0.461 per share on May 17
Shenwei Pharmaceutical (02877) announced that it intends to pay an interim dividend of HK$0.461 per share on May 17, 2024...
SHINEWAY PHARM: 2023 ANNUAL RESULTS ANNOUNCEMENT AND DECLARATION OF 2024 FIRST INTERIM DIVIDEND
Shenwei Pharmaceutical (2877.HK): Rapid growth in performance, smooth progress in research and development of new drugs
Incident: The company announced its 2023 results. Operating revenue was RMB 4,517 million, up 14.3% year on year, and net profit to mother was 970 million yuan, up 34.1% year on year. Review opinion: Rapid growth in performance, note
Shenwei Pharmaceutical (02877.HK) plans to hold a board meeting on March 28 to approve the annual results
Glonghui, March 18, 丨 Shenwei Pharmaceutical (02877.HK) announced that the company will hold a board meeting on Thursday, March 28, 2024 at Room 3109, 31/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong to (among others) approve the release of the company and its subsidiaries for the year ended 31 December 2023 and consider declaring dividends.
SHINEWAY PHARM: Notice of Board Meeting
Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose more than 5% to a new high, net profit pre-increased by more than 30% last year
Shenwei Pharmaceutical (02877) rose by more than 5%, reaching a new high of HK$10.1 since July 2018. As of press release, it rose 5.44% to HK$10.08, with a turnover of HK$29.741,900.
Express News | Debon Securities: Traditional Chinese medicine allocation is cost-effective, focus on small and medium capitalization stocks that have overfallen
China Shineway Pharmaceutical to Log Higher Profit in 2023; Shares Up 3%
China Shineway Pharmaceutical Group (HKG:2877) expects a 30% to 36% increase in its profit attributable to the owners for the year ended Dec. 31, 2023, compared with the 722.8 million yuan profit a ye
Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose more than 6% after earnings, and net profit is expected to increase by about 30% to 36% year-on-year last year
Shenwei Pharmaceutical (02877) rose more than 6% after earnings. As of press release, it rose 6.04% to HK$9.3, with a turnover of HK$2,505,900.
Analysis
Price Target
No Data
